Subpopulations (absolute quantities) | Patients with RMS (favorable localization of the primary tumor) | Patients with RMS (unfavorable localization of the primary tumor) | Р |
CD3+ | 19.5 ± 2.4 (n = 3) | 6.4 ± 1.9 (n = 10) | 0.006 |
CD3+ CD2+ | 29.5 ± 3.0 (n = 3) | 9.5 ± 3.8 (n = 7) | 0.013 |
CD3+ CD8+ | 16.3 ± 2.2 (n = 3) | 5.4 ± 1.4 (n = 9) | 0.003 |
CD5+ | 19.8 ± 2.5 (n = 3) | 5.9 ± 2.0 (n = 9) | 0.047 |
CD56+ | 3.4 ± 0.5 (n = 3) | 0.8 ± 0.2 (n = 8) | 0.000 |
CD19+ CD5+ | 16.2 ± 11.9 (n = 3) | 0.8 ± 0.4 (n = 8) | 0.044 |
αβTCR | 24.9 ± 1.6 (n = 3) | 8.2 ± 3.5 (n = 7) | 0.018 |
γδTCR | 4.1 ± 0.8 (n = 3) | 1.3 ± 0.4 (n = 7) | 0.005 |
CD8+ HLADR+ | 4.4 ± 1.6 (n = 2) | 1.7 ± 0.3 (n = 7) | 0.017 |